366P - Circulating microRNAs as novel promising biomarkers for early detection of tongue cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Head and Neck Cancers
Translational Research
Presenter Hidetoshi Tahara
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors H. Tahara1, Y. Nishiyama1, S. Okamoto1, S. Okano2, M. Tahara2
  • 1Hiroshima University Institute Of Biomedical & Health Sciences, Hiroshima University, 734-8553 - Hiroshima/JP
  • 2Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP

Abstract

Background

Screening for Head and Neck Cancer requires stable, easy to use, and sensitive biomarkers that show characteristic changes at an early stage and recurrent cancer. Recent studies have demonstrated that miRNAs stably exist in body fluids and their expression patterns in cancer patients are distinct from those in healthy individuals. In this study, we analyzed non-coding small RNAs including miRNAs that specifically exist in plasma of patients with tongue cancer as novel biomarkers.

Methods

Plasma levels of miRNAs and other non-coding small RNAs in patients with tongue cancer (n = 24) vs healthy individuals (n = 24) and in patients preoperative (n = 24) vs postoperative (n = 24) were performed by using NGS (Ion PGM, Life Technologies) . The data analysis was performed using software (GMP Genomics), and identified sequences that distinguished between tongue cancer and normal healthy individuals. Validation experiments are performed with real-time PCR. In further analysis, levels of expression were compared between with (n = 5) and without recurrence individuals (n = 12).

Results

Twenty circulating miRNAs and isomiRs (few nucleotide lacks and/or additions compared with mature miRNA sequences) that more or less in patient plasma compared with control (|Fold Change|>2.0, P 0.97). Those combinations of miRNAs demonstrated positive detection at stage I. The ratio (postoperative/preoperative) of a combination of microRNAs demonstrated promising difference between with and without recurrence individuals (p = 0.06, AUC=0.8) for prediction of recurrence.

Conclusions

We demonstrated four combinations of circulating miRNAs potentially useful for detection of early-stage head and neck cancer, and another combination that is worth characterizing as a predictor of postoperative recurrence.

Clinical trial indentification

Legal entity responsible for the study

Hiroshima university

Funding

The Japan Agency for Medical Research and Development (AMED)

Disclosure

H. Tahara: Stockfolder in MiRTeL.Co.Ltd. S. Okano: Merck Serono Co., Ltd. (lecture fee). M. Tahara: Merck Sharp & Dome, Pfizer, Astra Zeneca (advisory board, research funding), Bayer (advisory board, lecture honorarium), Eisai (lecture honorarium, research funding), Otsuka, Boehringer Ingelheim (lecture honorarium), Novartis (research funding). All other authors have declared no conflicts of interest.